Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.83 USD
-0.22 (-10.54%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.85 +0.03 (1.37%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Pacific Biosciences of California, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 632 | 773 | 1,045 | 320 | 49 |
Receivables | 37 | 19 | 24 | 17 | 15 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 57 | 50 | 25 | 14 | 13 |
Other Current Assets | 17 | 10 | 7 | 5 | 3 |
Total Current Assets | 742 | 852 | 1,101 | 356 | 81 |
Net Property & Equipment | 36 | 42 | 33 | 25 | 30 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 919 | 820 | 821 | 0 | 0 |
Deposits & Other Assets | 16 | 13 | 6 | 4 | 4 |
Total Assets | 1,746 | 1,767 | 2,007 | 414 | 148 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 16 |
Accounts Payable | 15 | 12 | 11 | 4 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 46 | 33 | 36 | 17 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 25 | 210 | 17 | 13 | 8 |
Total Current Liabilities | 95 | 263 | 72 | 39 | 49 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 2 | 25 | 2 | 2 |
Convertible Debt | 892 | 897 | 896 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 20 | 1 | 173 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,045 | 1,204 | 1,216 | 78 | 93 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,540 | 2,100 | 2,010 | 1,372 | 1,121 |
Retained Earnings | -1,839 | -1,532 | -1,218 | -1,037 | -1,066 |
Other Equity | 0 | -5 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 701 | 563 | 791 | 335 | 55 |
Total Liabilities & Shareholder's Equity | 1,746 | 1,767 | 2,007 | 414 | 148 |
Total Common Equity | 701 | 563 | 791 | 335 | 55 |
Shares Outstanding | 267.40 | 226.10 | 220.60 | 180.20 | 152.90 |
Book Value Per Share | 2.62 | 2.49 | 3.59 | 1.86 | 0.36 |
Fiscal Year End for Pacific Biosciences of California, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 510 | 562 | 632 | 768 | 830 |
Receivables | 32 | 30 | 37 | 30 | 24 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 69 | 67 | 57 | 68 | 68 |
Other Current Assets | 17 | 17 | 17 | 15 | 14 |
Total Current Assets | 628 | 677 | 742 | 882 | 936 |
Net Property & Equipment | 35 | 37 | 36 | 40 | 40 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 812 | 912 | 919 | 926 | 820 |
Deposits & Other Assets | 12 | 13 | 16 | 15 | 16 |
Total Assets | 1,509 | 1,670 | 1,746 | 1,898 | 1,848 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 17 | 21 | 15 | 16 | 17 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 22 | 22 | 46 | 35 | 27 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 26 | 20 | 25 | 124 | 219 |
Total Current Liabilities | 78 | 73 | 95 | 184 | 271 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 6 | 6 | 5 | 5 |
Convertible Debt | 893 | 893 | 892 | 892 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 20 | 20 | 20 | 893 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,017 | 1,021 | 1,045 | 1,135 | 1,206 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,584 | 2,566 | 2,540 | 2,522 | 2,335 |
Retained Earnings | -2,091 | -1,917 | -1,839 | -1,757 | -1,690 |
Other Equity | -1 | 0 | 0 | -2 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 493 | 649 | 701 | 764 | 642 |
Total Liabilities & Shareholder's Equity | 1,509 | 1,670 | 1,746 | 1,898 | 1,848 |
Total Common Equity | 493 | 649 | 701 | 764 | 642 |
Shares Outstanding | 272.30 | 272.30 | 267.40 | 250.50 | 249.80 |
Book Value Per Share | 1.81 | 2.38 | 2.62 | 3.05 | 2.57 |